Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 95

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 95
---
 11.19      04/27/2025                                                                      
                  01/03/2020                                                          472      11.19      01/03/2025                                                                      
                  01/03/2023                                                        1,416      19.27      01/03/2028                                                                      
                  07/12/2025                                                                                                   12,500                                             34,625  
  Li,             01/02/2015                                                        1,770      19.89      01/02/2025                                                                      
                  01/03/2020                                                          472      11.19      01/03/2025                                                                      
                  01/03/2023                                                        1,416      19.27      01/03/2028                                                                      
                  07/12/2025                                                                                                   12,500                                             34,625  
  Miller,         03/01/2022                                                        3,540      13.67      04/19/2027                                                                      
                  01/03/2023                                                        1,416      19.27      01/03/2028                                                                      
                  07/12/2025                                                                                                   12,500                                             41,550  

(1) “ Value of unexercised in-the-money
options” at financial year-end is calculated based on the difference between the closing prices of the Common Shares on the NASDAQ
on the last trading day of the fiscal year (December 31, 2024) of $2.77 and the exercise price of the options, multiplied by the number
of unexercised options.

(2) The Company used the closing price
of its Common Shares on the NASDAQ as at the last trading day of the fiscal year (December 31, 2024) of $2.77.

See “ Summary of the Stock Option Plan”
for more details on the Company’s second amended and restated stock option plan adopted by the Board on March 29, 2016 and ratified
by the shareholders on May 10, 2016 (“ Stock Option Plan”) and see “ Summary of Long-Term Incentive Plan”
for more details on the Company’s long-term incentive plan adopted by the Board on March 27, 2018, and ratified by the shareholders
on May 8, 2018 (“Long-Term Incentive Plan”